Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity

• Published in: Cancer letters Vol. 538; p. 215694
• Main Authors: Chamma, Hanane, Vila, Isabelle K., Taffoni, Clara, Turtoi, Andrei, Laguette, Nadine
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 10.07.2022; Elsevier Limited; Elsevier
• Subjects: Adenocarcinoma; Adipocytes; Antigen presentation; Cancer; Cancer therapies; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - therapy; Chemotherapy; Cytokines; Cytotoxicity; Fibroblasts; Human health and pathology; Humans; Hépatology and Gastroenterology; Immune response; Immunology; Immunotherapy; Inflammation; Interferon; Kinases; Life Sciences; Lymphocytes; Pancreas; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - therapy; Proteins; STING; Stroma; Tumor Microenvironment; Tumors; MDSC; Tumor microenvironment; Tregs; Inflammation; TME; DMXAA; PDAC; iCAFs; CAFs; DCs; Pancreatic cancer; Immunotherapy; cGAS; STING; CDNs; NK; pancreatic cancer; tumor microenvironment; inflammation; immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) is a cancer of poor prognosis that presents with a dense desmoplastic stroma that contributes to therapeutic failure. PDAC patients are mostly unresponsive to immunotherapy. However, hopes to elicit response to immunotherapy have emerged with novel strategies...